Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587698 | 0.80 | MPO (0.47) | TAAR1HTR2AHTR6 | |
| SCHEMBL73600 | 0.78 | L3MBTL1 (0.47) | — | |
| SCHEMBL15016169 | 0.76 | MTNR1A (0.47) | TAAR1 | |
| SCHEMBL8587766 | 0.76 | TAAR1 (0.48) | TAAR1HTR2AHTR6 | |
| SCHEMBL8587770 | 0.76 | TAAR1 (0.50) | TAAR1HTR2AADRA1AHTR6 | |
| SCHEMBL8589058 | 0.76 | TAAR1 (0.48) | TAAR1HTR2AHTR6 | |
| SCHEMBL8586513 | 0.75 | TAAR1 (0.53) | TAAR1HTR2AADRA1A | |
| SCHEMBL9122622 | 0.75 | TAAR1 (0.67) | TAAR1HTR2AADRA1A | |
| SCHEMBL31332014 | 0.75 | TAAR1 (0.67) | TAAR1HTR2AADRA1A | |
| SCHEMBL5639741 | 0.75 | L3MBTL1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | claimed |
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-4971974-A | ANOREXIGENIC AGENTS, BENZO B!THIENO 2,3-C!PYRIDINE COMPOUNDS | NEUREX CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | TAAR1 3319/4885HTR2A 2572/4885ADRA1A 490/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | TAAR1 2774/4885HTR2A 2468/4885ADRA1A 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.